Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05368285 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
A Phase 2 study, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 208
- Enrollment target
NCT05368285 is a Phase 2 study that has completed, run by Celldex Therapeutics. The registered enrollment target is 208 participants.
The verdict
NCT05368285, a Phase 2 study, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 208 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria
Interventions
- DRUG Matching Placebo
- BIOLOGICAL barzolvolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2022-05-19 |
| Est. Completion | 2024-12-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05368285
The ClinicalTrials.gov registry entry for NCT05368285 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT05368285 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05368285 about?
NCT05368285 is a clinical study titled "A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria". The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria
What is the current status of trial NCT05368285?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 208 participants. The study started on 2022-05-19. Estimated completion is 2024-12-20.
What interventions are being tested in trial NCT05368285?
The interventions under investigation include: Matching Placebo (DRUG), barzolvolimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05368285?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.